Scott Randal W.

DirectorBridgeBio Pharma, Inc. (BBIO) · full profile →Form 4 · filed May 19, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$671K
Net Open-Market Flow
-$671K
Transactions
6
5 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 15, 2026Option exercise(M)10K$16.75$168K22K
May 15, 2026Sell(S)6K$66.69$413K15K
May 15, 2026Sell(S)2K$67.53$141K13K
May 15, 2026Sell(S)2K$68.23$103K12K
May 15, 2026Sell(S)200$69.12$14K12K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 15, 2026Option exercise(M)10K$022K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001470831-26-000470) within minutes of acceptance. Every field above traces to the original document. Verify it directly: